Orsiro cobalt-chromium sirolimus-eluting stent: present and future perspectives.

Détails

ID Serval
serval:BIB_C35F997B1EAC
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Orsiro cobalt-chromium sirolimus-eluting stent: present and future perspectives.
Périodique
Expert review of medical devices
Auteur(s)
Iglesias J.F., Roffi M., Degrauwe S., Secco G.G., Aminian A., Windecker S., Pilgrim T.
ISSN
1745-2422 (Electronic)
ISSN-L
1743-4440
Statut éditorial
Publié
Date de publication
10/2017
Peer-reviewed
Oui
Volume
14
Numéro
10
Pages
773-788
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
New-generation drug-eluting stents (DES) represent the current standard of care in patients undergoing percutaneous coronary intervention (PCI). Biodegradable polymer DES (BP-DES) were recently developed to overcome current limitations of newer-generation durable polymer DES (DP-DES) attributed to sustained inflammatory responses induced by permanent polymers. The Orsiro DES (Biotronik AG, Bülach, Switzerland) is a novel thin-strut cobalt-chromium sirolimus-eluting stent with biodegradable polymer that features some of the latest developments in DES technology. Areas covered: This article aims to review the currently available evidence on the clinical performance of the Orsiro BP-DES and its future perspectives. Expert commentary: The Orsiro DES is a recent newer-generation BP-DES that combines a highly deliverable thin-strut cobalt-chromium stent platform and a unique hybrid concept with passive and active coatings designed to enhance tissue biocompatibility. In preclinical and intravascular imaging studies, the Orsiro BP-DES was shown to induce low inflammation and promote very early arterial healing. Recently, large randomized non-inferiority clinical trials have shown similar short- and mid-term efficacy and safety outcomes with Orsiro BP-DES compared with currently established newer-generation DES among all-comers and high-risk subgroups. The potential clinical superiority of Orsiro BP-DES over Xience DP-DES in patients with STEMI is currently investigated in the BIOSTEMI trial (NCT02579031).

Mots-clé
Absorbable Implants, Chromium Alloys, Drug-Eluting Stents, Forecasting, Humans, Percutaneous Coronary Intervention, Polymers, Prosthesis Design, Sirolimus/administration & dosage, Switzerland, Treatment Outcome, Biodegradable polymer, Orsiro drug-eluting stent, ST-elevation myocardial infarction, percutaneous coronary intervention, thin-struts stent
Pubmed
Web of science
Création de la notice
25/09/2017 16:20
Dernière modification de la notice
03/03/2018 21:11
Données d'usage